Mutual of America Capital Management’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,905
| Closed | -$69K | – | 1457 |
|
|
2022
Q3 | $69K | Buy |
2,905
+462
| +19% | +$10.6K | ﹤0.01% | 1576 |
|
|
2022
Q2 | $55K | Buy |
2,443
+363
| +17% | +$8.1K | ﹤0.01% | 1592 |
|
|
2022
Q1 | $52K | Buy |
2,080
+107
| +5% | +$3.26K | ﹤0.01% | 1606 |
|
|
2021
Q4 | $71K | Buy |
1,973
+50
| +3% | +$2K | ﹤0.01% | 1588 |
|
|
2021
Q3 | $82K | Sell |
1,923
-123
| -6% | -$5.07K | ﹤0.01% | 1570 |
|
|
2021
Q2 | $89K | Buy |
2,046
+133
| +7% | +$5.67K | ﹤0.01% | 1581 |
|
|
2021
Q1 | $78K | Buy |
1,913
+119
| +7% | +$4.51K | ﹤0.01% | 1587 |
|
|
2020
Q4 | $81K | Buy |
1,794
+71
| +4% | +$2.69K | ﹤0.01% | 1532 |
|
|
2020
Q3 | $61K | Buy |
1,723
+1,038
| +152% | +$37.5K | ﹤0.01% | 1511 |
|
|
2020
Q2 | $26K | Buy |
685
+49
| +8% | +$1.61K | ﹤0.01% | 1498 |
|
|
2020
Q1 | $18K | Buy |
636
+123
| +24% | +$4.97K | ﹤0.01% | 1507 |
|
|
2019
Q4 | $27K | Buy |
513
+1
| +0.2% | +$58 | ﹤0.01% | 1506 |
|
|
2019
Q3 | $28K | Buy |
512
+4
| +0.8% | +$205 | ﹤0.01% | 1490 |
|
|
2019
Q2 | $21K | Buy |
508
+100
| +25% | +$3.65K | ﹤0.01% | 1551 |
|
|
2019
Q1 | $12K | Buy |
408
+57
| +16% | +$1.95K | ﹤0.01% | 1615 |
|
|
2018
Q4 | $12K | Buy |
351
+73
| +26% | +$2.63K | ﹤0.01% | 1578 |
|
|
2018
Q3 | $12K | Sell |
278
-70,643
| -100% | -$2.79M | ﹤0.01% | 1587 |
|
|
2018
Q2 | $2.27M | Buy |
70,921
+54
| +0.1% | +$2.22K | 0.03% | 833 |
|
|
2018
Q1 | $3.52M | Buy |
70,867
+20,400
| +40% | +$1.15M | 0.05% | 568 |
|
|
2017
Q4 | $2.72M | Buy |
50,467
+336
| +0.7% | +$18.6K | 0.04% | 722 |
|
|
2017
Q3 | $2.91M | Hold |
50,131
| – | – | 0.05% | 650 |
|
|
2017
Q2 | $2.47M | Sell |
50,131
-2,750
| -5% | -$127K | 0.04% | 727 |
|
|
2017
Q1 | $2.3M | Sell |
52,881
-1,236
| -2% | -$59K | 0.04% | 738 |
|
|
2016
Q4 | $2.65M | Sell |
54,117
-273
| -0.5% | -$12.6K | 0.05% | 635 |
|
|
2016
Q3 | $2.6M | Hold |
54,390
| – | – | 0.05% | 601 |
|
|
2016
Q2 | $2.92M | Sell |
54,390
-17,500
| -24% | -$825K | 0.06% | 509 |
|
|
2016
Q1 | $3.21M | Buy |
71,890
+500
| +0.7% | +$20.3K | 0.07% | 418 |
|
|
2015
Q4 | $2.72M | Sell |
71,390
-733
| -1% | -$28K | 0.06% | 502 |
|
|
2015
Q3 | $2.3M | Hold |
72,123
| – | – | 0.05% | 572 |
|
|
2015
Q2 | $2.38M | Hold |
72,123
| – | – | 0.05% | 621 |
|
|
2015
Q1 | $2.97M | Sell |
72,123
-2,035
| -3% | -$82.3K | 0.06% | 498 |
|
|
2014
Q4 | $3.02M | Buy |
74,158
+20,184
| +37% | +$789K | 0.07% | 462 |
|
|
2014
Q3 | $1.98M | Buy |
53,974
+14,685
| +37% | +$635K | 0.05% | 673 |
|
|
2014
Q2 | $1.82M | Buy |
39,289
+14,654
| +59% | +$652K | 0.04% | 740 |
|
|
2014
Q1 | $1.01M | Buy |
+24,635
| New | +$916K | 0.02% | 972 |
|
Other funds holding ANIK
TI
CP
BFM
PCM
Mutual of America Capital Management's ANIK Position: Q4 2022 in Review
Mutual of America Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2022, closing a stake of 2,905 shares — an estimated $69K sold.
Mutual of America Capital Management first reported a position in ANIK in Q1 2014 and held it in 35 quarters. The position peaked at $3.52M in Q1 2018. 125 funds tracked by Wall St. Rank hold ANIK as of Q4 2022.
- Mutual of America Capital Management reported no remaining Anika Therapeutics position as of Q4 2022 after selling out during the quarter.
- Mutual of America Capital Management sold 2,905 Anika Therapeutics shares in Q4 2022, an estimated $69K.
- Mutual of America Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 35 quarters.
- Mutual of America Capital Management's Anika Therapeutics position peaked at $3.52M in Q1 2018.
- 125 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2022.
Based on Mutual of America Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.